The Asia Pacific Blood Glucose Monitoring System Market value is projected to reach US$ 1.58 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 4.6%. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology :- Request Free Sample Report Blood glucose monitoring is used for revealing individual patterns related to blood glucose changes based on which planning can be done for meals, activities as well as medications. In addition to this, testing allows quick response in case of higher or lower blood sugar level. This includes diet adjustments and exercises as well or insulin in case prescribed by the physician or healthcare provider. Generally, without diabetes, human body tracks levels of glucose all day and night for ensuring the exact amount of insulin is released when required at the right time. For successfully managing diabetes, monitoring systems are required for consistently checking glucose levels and take precautions accordingly. The Asia-pacific blood glucose monitoring system market has been bifurcated on the basis of product, testing type, patient care setting, application, and geography. The product segment for the market has been divided into self-monitoring and continuous monitoring systems. Self-monitoring systems held a larger market share as compared to continuous systems, which maintained high CAGR growth during the forecast period. Continuous monitoring systems use a disposable sensor placed right under the skin and is kept there until further replacement. This sensor forms a link between non-implanted transmitter and radio receiver that is used for further communication. Continuous systems measure the glucose concentration within any normal sample of interstitial fluid which has led to its growth in the last few years. Self-monitoring systems provide easier access to information and are cost-efficient as well that has led to its market dominance. Based on the testing type, fingertip testing holds a larger market share as compared to alternate testing. Easier access to blood ejaculation along with less pain has led to the fingertip being used majorly for testing purpose. Patient care setting bifurcates the market into homecare and hospitals where homecare dominates the market. Rising awareness about diabetes and blood glucose monitoring machines have formed two major drivers for the growth of home care segment. In addition to this, factors such as easier availability of monitoring machines and cost-effectiveness have further helped homecare segment to hold dominance over hospitals. The Asia Pacific is likely to account one of the fastest growth for blood glucose monitoring system globally. China, Japan, and India have formed some of the major countries contributing to overall market growth. There has been a surge in the number of patients suffering from diabetes that has eventually led pharmaceutical companies to look for systems to provide faster information regarding glucose level along with better precision. All these factors have together helped in the high growth of the blood glucose monitoring system in the Asia Pacific.
Asia-Pacific Blood Glucose Monitoring System Market Key Highlights:• Asia-Pacific Blood Glucose Monitoring System market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Asia-Pacific Blood Glucose Monitoring System market • Blood Glucose Monitoring System market segmentation on the basis of product, testing type, patient care setting, application, and geography. • Blood Glucose Monitoring System market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of the study • Blood Glucose Monitoring System market analysis and forecast for major countries has been provided. • Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies • Competitive landscape of the key players operating in the Blood Glucose Monitoring System market including competitive developments, investments, and strategic expansion
Asia-Pacific Blood Glucose Monitoring System Market Research Methodology:The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for Asia-Pacific Blood Glucose Monitoring System market
Some of the key players of the Asia-Pacific Blood Glucose Monitoring System market include:• Nipro • ARKRAY • Novo Nordisk • Abbott Laboratories • Shenzhen Group • Daiichi Sankyo • Takeda Pharmaceutical Co Ltd. • Roche Diagnostics • Sanofi • GlaxoSmilth Kline • Merck
Asia-Pacific Blood Glucose Monitoring System Market Key Target Audience:• Blood glucose monitoring systems and related devices manufacturers • Hospitals, diagnostic centers, homecare service providers, and medical colleges • Teaching hospitals and academic medical centers • Suppliers and distributors of blood glucose monitoring systems • Government bodies or municipal corporations
Scope of the Blood Glucose Monitoring System Market Report: Inquire before buyingThe research report segments Asia-Pacific Blood Glucose Monitoring System market based on product, testing site, patient care setting, application and geography.
Blood Glucose Monitoring System Market, By Product:• Self-Monitoring Blood Glucose Systems • Blood Glucose meters • Testing strips • Lancets & Lancing Devices • Continuous Glucose Monitoring Systems • Sensors • Transmitters • Receivers
Blood Glucose Monitoring System Market, By Testing Site:• Fingertip testing • Alternate Site Testing
Blood Glucose Monitoring System Market, By Patient Care Setting:• Self/Home Care • Hospital & Clinics
Blood Glucose Monitoring System Market, By Application:• Type 2 Diabetes • Type 1 Diabetes • Gestational Diabetes
Blood Glucose Monitoring System Market, By Geography:• Asia-Pacific • China • Japan • India • South Korea • Australia • Others
Geographic Analysis:• Breakdown of China Blood Glucose Monitoring System market • Breakdown of Japan Blood Glucose Monitoring System market • Breakdown of India Blood Glucose Monitoring System market • Breakdown of South Korea Blood Glucose Monitoring System market • Breakdown of Australia Blood Glucose Monitoring System market • Breakdown of Others Blood Glucose Monitoring System market
Available Customization:Maximize Market Research offers customization of reports according to the specific requirement of our clients
Blood Glucose Monitoring System Market1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES SCOPE 3.1. Market Segmentation Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political legal, economic and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. Product ESTIMATES TREND ANALYSIS (2019 – 2026) 4.1. Blood Glucose Monitoring System Market: Product Analysis 4.2. Self-Monitoring Blood Glucose Systems 4.2.1. Self-Monitoring Blood Glucose Systems market, 2019 – 2026 (USD billion) 4.3. Continuous Glucose Monitoring Systems 4.3.1. Continuous Glucose Monitoring Systems market, 2019 – 2026 (USD billion) 5. TESTING SITE ESTIMATES TREND ANALYSIS (2019 – 2026) 5.1. Blood Glucose Monitoring System Market: Testing Site Analysis 5.2. Fingertip 5.2.1. Fingertip market, 2019 – 2026 (USD billion) 5.3. Alternate Site 5.3.1. Alternate Site market, 2019 – 2026 (USD billion) 6. PATIENT CARE SETTING ESTIMATES TREND ANALYSIS (2019 – 2026) 6.1. Blood Glucose Monitoring System Market: Patient Care Setting Analysis 6.2. Self/Home Care 6.2.1. Self/Home Care market, 2019 – 2026 (USD billion) 6.3. Hospital Clinics 6.3.1. Hospital Clinics market, 2019 – 2026 (USD billion) 7. APPLICATION ESTIMATES TREND ANALYSIS (2019 – 2026) 7.1. Blood Glucose Monitoring System Market: Application Analysis 7.2. Type 2 Diabetes 7.2.1. Type 2 Diabetes market, 2019 – 2026 (USD billion) 7.3. Type 1 Diabetes 7.3.1. Type 1 Diabetes market, 2019 – 2026 (USD billion) 7.4. Gestational Diabetes 7.4.1. Gestational Diabetes market, 2019 – 2026 (USD billion) 8. REGIONAL ESTIMATES TREND ANALYSIS BY PRODUCT, TESTING TYPE, PATIENT CARE SETTING AND APPLICATION (2019 – 2026) 8.1. Blood Glucose Monitoring System market share by country, 2019-2026 8.2. China 8.2.1. China Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.3. Japan 8.3.1. Japan Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.4. India 8.4.1. India Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.5. South Korea 8.5.1. South Korea Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.6. Australia 8.6.1. Australia Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.7. Others 8.7.1. Others Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. Nipro 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.2. ARKRAY 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.3. Novo Nordisk 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.4. Abbott Laboratories 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.5. Shenzhen Group 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.6. Daiichi Sankyo 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.7. Takeda Pharmaceutical Co Ltd. 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.8. Roche Diagnostics 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.9. Sanofi 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.10. GlaxoSmilth Kline 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.11. Merck 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives